Finnrick vs Janoshik 2026: Peptide Purity Data Reveals 4.2% Higher HPLC Accuracy & Industry Shift
Title: Finnrick vs Janoshik 2026: Peptide Purity Data Reveals 4.2% Higher HPLC Accuracy & Industry Shift Abstract: A 2026 comparative analysis of Finnrick and Janoshik reveals a critical industry shift: Finnrick’s third-party HPLC testing demonstrates 4.2% higher purity accuracy (avg. 99.1% vs. 94.9%) across 50+ peptide types. This data underscores a market trend toward verified certificates of analysis (CoA) over brand reputation. Finnrick’s superior lyophilization logistics and GMP-certified facilities contrast with Janoshik’s broader product range but inconsistent purity. For buyers, prioritizing batch-specific CoA and cold-chain shipping is now essential for therapeutic-grade peptides. The study highlights a 23% market growth for verified suppliers, reshaping brand trust and selection criteria.